The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients
Korean Journal of Hepatology 2014³â 20±Ç 1È£ p.38 ~ p.46
Á¤ÈñÀç(Jung Hee-Jae) - Soonchunhyang University Bucheon Hospital Department of Internal Medicine
±è¿µ¼®(Kim Young-Seok) - Soonchunhyang University Bucheon Hospital Department of Internal Medicine
±è»ó±Õ(Kim Sang-Gyune) - Soonchunhyang University Bucheon Hospital Department of Internal Medicine
ÀÌÀ±³ª(Lee Yun-Nah) - Soonchunhyang University Bucheon Hospital Department of Internal Medicine
Á¤½Â¿ø(Jeong Soung-Won) - Soonchunhyang University College of Medicine Soonchunhyang University Seoul Hospital Department of Internal Medicine
ÀåÀ翵(Jang Jae-Young) - Soonchunhyang University College of Medicine Soonchunhyang University Seoul Hospital Department of Internal Medicine
À̼¼È¯(Lee Sae-Hwan) - Soonchunhyang University College of Medicine Soonchunhyang University Cheonan Hospital Department of Internal Medicine
±èÈ«¼ö(Kim Hong-Soo) - Soonchunhyang University College of Medicine Soonchunhyang University Cheonan Hospital Department of Internal Medicine
±èºÎ¼º(Kim Boo-Sung) - Soonchunhyang University Bucheon Hospital Department of Internal Medicine
Abstract
Background/Aims: Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was to determine the association between CHC treatment response and lipid profile and IR change during treatment.
Methods: In total, 203 CHC patients were reviewed retrospectively between January 2005 and December 2011 at Soon Chun Hyang University Hospital. The lipid profile, homeostasis model for assessment (HOMA) of IR (HOMA-IR), and HOMA of ¥â cells (HOMA-¥â) were evaluated before interferon plus ribavirin therapy (BTx), at the end of treatment (DTx), and 24 weeks after the end of treatment (ATx).
Results: A sustained virologic response (SVR) was achieved by 81% of all patients (49/60), 60% (n=36) of whom possessed genotype 1, with the remainder being non-genotype-1 (40%, n=24). Apart from age, which was significantly higher in the non-SVR group (SVR, 48.0¡¾11.2 years, mean¡¾SD; non-SVR, 56.6¡¾9.9 years; P<0.01), there were no significant differences in the baseline characteristics between the SVR and non-SVR groups. In the SVR group, low density lipoprotein-cholesterol (LDL-C) had significantly changed at DTx and ATx compared to BTx. In addition, HOMA-IR and HOMA-¥â were significantly changed at DTx in the SVR group. Among those with a high baseline insulin resistance (HOMA-IR >2.5), HOMA-IR was significantly changed at DTx in the SVR group.
Conclusions: LDL-C appears to be associated with HCV treatment in SVR patients. Furthermore, eradication of HCV may improve whole-body IR and insulin hypersecretion, as well as high baseline insulin resistance (HOMA-IR >2.5).
Å°¿öµå
Lipid metabolism, Insulin resistance, Chronic hepatitis C
KMID :
1103920140200010038
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)